David C. Magnus, Ph.D.

Administrative Appointments

• Chair, Program in Regenerative Medicine Sub-Committee on Bioethics and Conflict of Interest , (2005– present )
• Co-Director, Scholarly Concentration in Biomedical Ethics and Medical Humanities , (2003– present )
• Co-Chair, Stanford Hospital and Clinics Ethics Committee , (2003– present )
• Director, Stanford Center for Biomedical Ethics , (2003– present )

Honors and Awards

• Expert for World Bank on Food Security and Biotechnology, The World Bank (2000)
• Secretary of Agriculture's Advisory Committee on Biotechnology and the 21st Century (Member), Agriculture Advisory Committee (2003)
• Committee on Biological Confinement of Genetically Engineered Organisms (Member), National Research Council of the Academies (2002-2003)
• E.G. Young Seminar, Chemical Institute of Canada (2000)
• Best New Journal Award, Council of Editors of Learned Journals for the American Journal of Bioethics (2004)
• Arnold G. Wedum Memorial Lecture, American Biological Safety Association (2003)
• Woodrow Wilson Convocation Speaker, Clarkson University (2002)
• Moral and Social Consequences of the Human Genome Project, Oregon State University (2001)

Professional Education

• Ph.D., Stanford University Philosophy
• B.A., UC Riverside Philosophy

Web Site Links

• Center for Biomedical Ethics

Research Interests

Genetic testing, gene therapy, genetically engineered organisms, and the history of eugenics. Stem cell research and cloning, and egg procurement. Examining ethical issues in reproductive technologies. Organ transplantation – including donation after cardiac death, ethics of listing decisions. End of life issues in both adults and children.

Publications

• Use of neurodevelopmental delay in pediatric solid organ transplant listing decisions: inconsistencies in standards across major pediatric transplant centers. Richards CT,  Crawley LM, Magnus D.  Pediatr Transplant.  2009; 13 (7): 843-50
• Direct-to-consumer genetic tests: beyond medical regulation? Magnus D,  Cho MK, Cook-Deegan R.  Genome Med.  2009; 1 (2): 17
• Research ethics consultation: the Stanford experience. Cho MK,  Tobin SL, Greely HT, McCormick J, Boyce A, Magnus D.  IRB.  2008 Nov-Dec; 30 (6): 1-6
• Response to Open Peer Commentaries on "Strangers at the Beachside: Research Ethics Consultation" Cho MK,  Tobin SL, Greely HT, McCormick J, Boyce A, Magnus D.  Am J Bioeth.  2008; 8 (3): 4-6
• Strangers at the benchside: research ethics consultation. Cho MK,  Tobin SL, Greely HT, McCormick J, Boyce A, Magnus D.  Am J Bioeth.  2008; 8 (3): 4-13
• The green revolution in bioethics. Magnus D,  Am J Bioeth.  2008; 8 (8): 1-2
• Blood, sweat and tears. Magnus D,  Am J Bioeth.  2006 May-Jun; 6 (3): 1-2
• A commentary on oocyte donation for stem cell research in South Korea. Magnus D,  Cho MK.  Am J Bioeth.  2006 Jan-Feb; 6 (1): W23-4
• Stem cell research: the California experience. Magnus D,  Hastings Cent Rep.  2006 Jan-Feb; 36 (1): 26-8
• Research conduct. Lessons of the stem cell scandal. Cho MK,  McGee G, Magnus D.  Science.  2006; 311 (5761): 614-5
• Ethics. Issues in oocyte donation for stem cell research. Magnus D,  Cho MK.  Science.  2005; 308 (5729): 1747-8
• Stem cell research should be more than a promise. Magnus D,  Hastings Cent Rep.  2004 Sep-Oct; 34 (5): 35-6
• Politics and peer review. Magnus D,  Am J Bioeth.  2004; 4 (1): 7-8
• New life forms: new threats, new possibilities. Caplan AL,  Magnus D.  Hastings Cent Rep.  2003 Nov-Dec; 33 (6): 7
• Protecting subjects' interests in genetics research. Merz JF,  Magnus D, Cho MK, Caplan AL.  Am J Hum Genet.  2002; 70 (4): 965-71
• The meaning of graduate education for bioethics. Magnus D,  Am J Bioeth.  2002; 2 (4): 10-2
• In focus. Core faculty and their publications at bioethics centers in the United States. Magnus D,  Miller V, Carroll K.  Am J Bioeth.  2002; 2 (4): W20
• Evaluating graduate programs in bioethics: what measures should we use? McGee G,  Magnus D, Carroll K.  Am J Bioeth.  2002; 2 (4): 1-2
• Is there a bioethicist in your company? Should there be? Magnus D,  Drug Discov Today.  2002; 7 (7): 385-7
• David Magnus,  Ed. with Art Caplan and Glenn McGee.  Who Owns Life?.  2002;
• Bioethics programs evolve as they grow. Magnus D,  Nat Biotechnol.  2001; 19 (10): 991-2
• NAS cloning hearing disappoints participants. Magnus D,  Caplan A.  Science.  2001; 294 (5547): 1651
• Family problems. Magnus D,  Dagostino L.  Am J Bioeth.  2001; 1 (3): 1
• Reason and repugnance. Callahan D,  Magnus D.  Med Ethics (Burlingt Mass).  2001; 6-7
• Ethical issues: from genome to therapy. Magnus D,  Novartis Found Symp.  2000; 229 122-5; discussion 125-30
• Policy forum: genetics. Ethical considerations in synthesizing a minimal genome. Cho MK,  Magnus D, Caplan AL, McGee D.  Science.  1999; 286 (5447): 2087, 2089-90
• What is immoral about eugenics? Caplan AL,  McGee G, Magnus D.  BMJ.  1999; 319 (7220): 1284-5
• Disease gene patenting: the clinician's dilemma. Magnus D,  Camb Q Healthc Ethics.  1998; 7 (4): 433-5